124 related articles for article (PubMed ID: 3931992)
1. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
Bayer AS; Lam K; Norman D; Kim KS; Morrison JO
Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
Bayer AS; Norman D; Kim KS
Antimicrob Agents Chemother; 1985 Dec; 28(6):781-5. PubMed ID: 3909954
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
Bayer AS; Kim KS
Chemotherapy; 1986; 32(4):364-73. PubMed ID: 2942342
[TBL] [Abstract][Full Text] [Related]
4. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
Bayer AS; Hirano L; Yih J
Antimicrob Agents Chemother; 1988 Feb; 32(2):231-5. PubMed ID: 3129985
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination.
Shyu WC; Nightingale CH; Quintiliani R
J Antimicrob Chemother; 1987 Jun; 19(6):807-14. PubMed ID: 3112102
[TBL] [Abstract][Full Text] [Related]
6. Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa.
Van Laethem Y; Klastersky J
Eur J Clin Microbiol; 1986 Feb; 5(1):110-4. PubMed ID: 3084239
[TBL] [Abstract][Full Text] [Related]
7. Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.
Van der Auwera P; Klastersky J; Lagast H; Husson M
Antimicrob Agents Chemother; 1986 Jul; 30(1):122-6. PubMed ID: 3092729
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae.
Moody JA; Fasching CE; Peterson LR; Gerding DN
Diagn Microbiol Infect Dis; 1987 Jan; 6(1):59-67. PubMed ID: 3100127
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis.
Bayer AS; Crowell DJ; Yih J; Bradley DW; Norman DC
J Infect Dis; 1988 Aug; 158(2):355-9. PubMed ID: 3042875
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.
Bayer AS; Lindsay P; Yih J; Hirano L; Lee D; Blomquist IK
Antimicrob Agents Chemother; 1986 Oct; 30(4):528-31. PubMed ID: 3539007
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.
Bayer AS; Selecky M; Babel K; Hirano L; Yih J; Parr TR
Antimicrob Agents Chemother; 1987 Nov; 31(11):1750-5. PubMed ID: 3124738
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
Schaad UB; Wedgwood-Krucko J; Suter S; Kraemer R
J Pediatr; 1987 Oct; 111(4):599-605. PubMed ID: 3309236
[TBL] [Abstract][Full Text] [Related]
13. The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat.
Ingerman MJ; Pitsakis PG; Rosenberg AF; Levison ME
J Infect Dis; 1986 Apr; 153(4):707-14. PubMed ID: 2936832
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.
Johnson DE; Thompson B
Am J Med; 1986 May; 80(5C):53-8. PubMed ID: 3636060
[TBL] [Abstract][Full Text] [Related]
15. Oxygen-dependent differences in exopolysaccharide production and aminoglycoside inhibitory-bactericidal interactions with Pseudomonas aeruginosa--implications for endocarditis.
Bayer AS; O'Brien T; Norman DC; Nast CC
J Antimicrob Chemother; 1989 Jan; 23(1):21-35. PubMed ID: 2501267
[TBL] [Abstract][Full Text] [Related]
16. In-vitro and in-vivo bacterocodal interactions of clindamycin and ceftazidime, by non-beta-lactamase mechanisms, in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive beta-lactamase overproducing strain.
Bayer AS; Lindsay P; Parr TR
J Antimicrob Chemother; 1988 Oct; 22(4):529-39. PubMed ID: 3144525
[TBL] [Abstract][Full Text] [Related]
17. Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.
Johnson DE; Thompson B; Calia FM
Antimicrob Agents Chemother; 1985 Dec; 28(6):735-9. PubMed ID: 3909952
[TBL] [Abstract][Full Text] [Related]
18. Role of beta-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis.
Bayer AS; Peters J; Parr TR; Chan L; Hancock RE
Antimicrob Agents Chemother; 1987 Feb; 31(2):253-8. PubMed ID: 3105450
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa resistance to ceftazidime.
Balagué M; Del Valle O; Figueras A; Arnau JM
DICP; 1991; 25(7-8):871. PubMed ID: 1949952
[No Abstract] [Full Text] [Related]
20. Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.
Standiford HC; Drusano GL; Fitzpatrick B; Tatem B; Schimpff SC
Antimicrob Agents Chemother; 1984 Sep; 26(3):339-42. PubMed ID: 6439114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
